The 2022 Krka Annual Report PDF is the primary official record of the financial performance, strategic direction, and sustainability initiatives of Krka, d. d., Novo mesto. It details the company's record-breaking revenue of €1,717.5 million and provides a comprehensive breakdown of its operations across more than 70 markets, serving as a vital resource for investors and analysts.
Introduction to the 2022 Krka Annual Report
For investors and financial professionals operating in 2026, the 2022 Krka Annual Report remains a foundational document. It captures a pivotal moment in the history of the Slovenian pharmaceutical giant, marking a period of significant geopolitical volatility and subsequent corporate resilience. As one of the world’s leading generic pharmaceutical companies, Krka's reporting standards are rigorous, complying with both International Financial Reporting Standards (IFRS) as adopted by the European Union and the European Single Electronic Format (ESEF).
The 2022 report is not merely a collection of balance sheets; it is a narrative of how a vertically integrated business model can withstand global supply chain disruptions and regional conflicts. By analyzing this specific PDF, stakeholders gain insight into Krka’s "Region East" operations, which include Russia and Ukraine—markets that were under intense scrutiny during that fiscal year.
How to Access the Official 2022 Krka Annual Report PDF
Locating the verified version of the annual report is crucial for data integrity. As of 2026, Krka maintains a robust archive of its historical financial disclosures.
Official Krka Investor Relations Portal
The most reliable source for the report is the official Krka Investor Relations page. Krka typically provides the report in two formats:
- The Integrated Annual Report (PDF): A user-friendly, high-design document intended for general reading and strategic review.
- The ESEF Format: A technical file (often a .zip containing XHTML) required for regulatory compliance within the EU, designed for machine-readable financial analysis.
Regulatory Repositories
Because Krka is listed on the Ljubljana Stock Exchange (LJSE) and the Warsaw Stock Exchange (WSE), the 2022 report is also archived on SEOnet, the official system for information dissemination of the Ljubljana Stock Exchange. This portal provides a timestamped record of the disclosure, ensuring that the version you are viewing is the legally filed original.
Core Financial Performance in 2022
The 2022 fiscal year was characterized by "growth in challenging times." For an analyst, the PDF reveals how the company managed to increase sales by 10% compared to 2021 despite the devaluation of the Russian rouble and the logistical hurdles posed by the conflict in Ukraine.
Revenue Breakdown by Region
Krka’s sales strategy is heavily diversified across several key regions. The 2022 report identifies "Region East" as the largest sales territory, contributing 36.1% of total sales. Within this region, the Russian Federation remained Krka's strongest individual market. "Region Central Europe" followed, representing 22.4% of sales, with Poland playing a central role.
Profitability and Margins
The 2022 report highlighted a net profit of €363.6 million, an increase of 18% over the previous year. This was achieved through a combination of volume growth and efficient management of operating expenses. The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) margin remained strong, reflecting the company’s ability to control production costs through its vertically integrated model—where Krka develops and manufactures a large portion of its own active pharmaceutical ingredients (APIs).
Strategic Business Segments and Product Portfolio
The 2022 annual report provides a deep dive into the therapeutic areas that drive Krka's value. Understanding these segments is essential for predicting the company's long-term stability.
Prescription Pharmaceuticals
This segment is the engine of the company, accounting for over 80% of total sales. The 2022 data shows continued dominance in:
- Cardiovascular Diseases: Medications for hypertension and cholesterol management.
- Central Nervous System (CNS): Treatments for depression, schizophrenia, and Alzheimer’s disease.
- Gastrointestinal Tract: Proton pump inhibitors and other digestive health products.
Non-Prescription Products and Animal Health
The report also details the performance of over-the-counter (OTC) brands like Septolete and Herbion. Additionally, Krka’s animal health segment showed robust growth in 2022, focusing on companion animal parasite treatments, which have historically higher margins than livestock medications.
Managing Geopolitical Risk: The Russia-Ukraine Context
One of the most critical sections of the 2022 Krka Annual Report PDF is the management's discussion of the conflict in Ukraine. Krka has long-standing manufacturing facilities in the Russian Federation (Krka-Rus).
The report details how the company:
- Ensured Supply Continuity: By maintaining local production and leveraging diversified logistics routes, Krka ensured that essential medicines reached patients in both Russia and Ukraine.
- Currency Hedging: The document explains the impact of the Russian rouble's volatility on the company's financial statements and the strategies used to mitigate exchange rate risks.
- Ethical Responsibility: Krka emphasized its commitment to the "right to health," justifying its continued presence in these markets as a provider of life-saving medicines rather than a purely commercial entity.
Sustainability and ESG Reporting
By 2022, Environmental, Social, and Governance (ESG) reporting had become a mandatory and integral part of Krka’s annual disclosure. The 2022 report follows the GRI (Global Reporting Initiative) standards.
Environmental Impact
Krka reported significant strides in reducing its carbon footprint. The 2022 report tracks energy efficiency, water usage, and waste management across its production sites in Slovenia, Croatia, Poland, Germany, and Russia. A key metric included was the reduction of specific greenhouse gas emissions relative to production volume.
Social and Governance Metrics
The "Social" section highlights Krka’s role as a major employer, with over 11,500 employees globally at the end of 2022. It covers employee safety, continuous education programs, and the company's "Krka Awards" for scientific research. From a governance perspective, the report outlines the composition of the Management Board and Supervisory Board, ensuring transparency in decision-making processes.
2022 Financial Summary Table
To help readers quickly verify the core data found within the PDF, the following table summarizes the key consolidated financial indicators for the Krka Group.
| Financial Indicator (Krka Group) | 2022 (Actual) | 2021 (Actual) | Change (%) |
|---|---|---|---|
| Revenue (Sales) | €1,717.5 Million | €1,565.8 Million | +10% |
| EBITDA | €488.9 Million | €463.6 Million | +5% |
| EBIT (Operating Profit) | €381.2 Million | €354.6 Million | +7% |
| Net Profit | €363.6 Million | €308.2 Million | +18% |
| Earnings Per Share (EPS) | €11.82 | €10.05 | +18% |
| Dividends Per Share | €6.63 | €5.63 | +17.8% |
| R&D Expenses | €163.0 Million | €153.5 Million | +6% |
Investor Relations and Dividend Policy
For shareholders reading the 2022 report, the dividend policy is often the most scrutinized section. Krka has a consistent track record of increasing dividends. Following the 2022 results, the company proposed a dividend of €6.63 per share, which represented a nearly 18% increase from the previous year’s payout.
The report clarifies the company's policy of allocating approximately 50% of the net profit of the majority shareholders to dividend payments, while also considering the capital needs for future investments and acquisitions.
Analyzing the Auditor’s Report
A critical component of the 2022 Krka Annual Report PDF is the Independent Auditor’s Report, typically provided by a major firm (in 2022, this was KPMG). The auditor provides an "unqualified opinion," meaning that the financial statements present a true and fair view of the company’s financial position.
Key Audit Matters (KAMs) highlighted in the 2022 report usually include:
- Revenue Recognition: Ensuring sales are recorded in the correct period across various international jurisdictions.
- Inventory Valuation: Assessing the value of raw materials and finished products, particularly in markets with high inflation or currency volatility.
- Litigation and Provisions: Evaluating the potential financial impact of patent disputes, which are common in the generic pharmaceutical industry.
Technical Specifications of the PDF Document
When downloading the 2022 report, users should ensure they have the "Full Version" rather than a "Summary" or "Presentation."
- File Size: Typically ranges from 10MB to 25MB due to high-resolution charts and images.
- Page Count: Usually exceeds 200 pages, covering the Business Report, Accounting Report, and Sustainability Report.
- Searchability: The PDF is fully indexed, allowing users to search for specific terms like "atorvastatin," "Rouble," or "ESG."
Common Troubleshooting and FAQs
Why can't I find the 2022 report on the Krka homepage?
As time passes, older reports are moved from the "Current Results" section to the "Archive" or "Past Reports" section within the Investor Relations tab. In 2026, you will need to look under the "Financial Reports Archive."
What is the difference between the Krka d.d. and Krka Group reports?
The Krka Group report (Consolidated) includes all subsidiaries and manufacturing sites worldwide. The Krka d.d. report (Parent) covers only the Slovenian parent company. Most investors should focus on the Consolidated Krka Group report for a complete picture of the business.
Is the 2022 report available in languages other than English?
Yes, Krka publishes its annual reports in both Slovenian and English. The English version is the standard for international investors and is what most "2022 krka annual report pdf" searches intend to find.
How did the 2022 report address patent litigation?
The 2022 document contains a specific section on "Legal Claims" under the notes to the financial statements. It details ongoing challenges by originator companies and the provisions Krka has set aside for potential settlements.
Recommendations for Further Research
While the 2022 Krka Annual Report PDF provides a comprehensive historical snapshot, a thorough analysis in 2026 should also include:
- Quarterly Reports for 2023-2025: To see how the trends established in 2022 evolved.
- Official Stock Exchange Notices: For any retrospective adjustments or significant events that occurred after the 2022 report was published.
- The 2026 Strategy Document: Krka periodically updates its five-year strategic plan; comparing the 2022 outcomes against these long-term goals is a powerful exercise for analysts.
By examining the 2022 report with a focus on both the hard financial data and the qualitative management commentary, stakeholders can better understand the intrinsic value and risk profile of Krka as it continues to navigate the global pharmaceutical landscape.
